Are there peptides that treat autoimmune diseases?
No peptide is FDA-approved to treat rheumatoid arthritis, lupus, multiple sclerosis, inflammatory bowel disease, or other common autoimmune conditions. That is the most important fact on this page. Some peptides have real research interest, and one (Lupuzor/P140) has reached late-stage lupus trials, but none is an approved autoimmune treatment, and most of the dramatic claims you see online are not backed by controlled human trials.
If you have an autoimmune disease, the evidence-based treatments are the ones your rheumatologist or specialist prescribes: DMARDs, biologics, and other approved therapies. Peptides are not a proven substitute.
| Peptide | Studied for | Evidence | Status |
|---|---|---|---|
| Thymosin alpha-1 | Immune modulation | Human trials abroad, not for autoimmune specifically | Not US-approved |
| BPC-157 | Gut/tissue repair | Mostly animal | Not approved; FDA Cat 2 (2023) |
| LL-37 | Antimicrobial/immune | Lab and early studies | Not approved |
| Lupuzor (P140) | Lupus (SLE) | Late-stage clinical trials | Investigational, not approved |
Can peptides help lupus?
The most legitimate autoimmune peptide story is Lupuzor (P140, forigerimod), a tolerogenic peptide developed specifically for systemic lupus erythematosus. It has progressed through clinical trials, including Phase III, and is the furthest-developed peptide aimed at lupus. But it is investigational and not yet an approved, commercially available treatment.
The peptides commonly marketed for lupus online, such as BPC-157 or thymosin alpha-1, are not proven lupus treatments. Claims of specific percentage reductions in lupus disease activity from these compounds are not supported by published controlled human trials.
Is BPC-157 good for autoimmune disease?
BPC-157 is marketed for gut healing, which appeals to people with IBD or the gut-immune axis. The reality: BPC-157 evidence is almost entirely from animal studies, there are no large human autoimmune trials, and it is not FDA-approved. In 2023 the FDA placed it in Category 2 of its compounding bulk substances list, citing safety concerns. The "68 percent reduction" and "78 percent of Crohn's patients improved" figures on the old page are not verifiable and should not guide treatment decisions.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Does thymosin alpha-1 help autoimmune conditions?
Thymosin alpha-1 is the best-studied immune-modulating peptide, with human trials abroad, but those trials are mainly for chronic hepatitis B and as a cancer-treatment adjunct, not for autoimmune diseases like RA or lupus. It is not FDA-approved in the US, and its US compounding was further restricted in 2023. So while it is a real immunomodulator, using it for autoimmune disease is off-label, unapproved, and not supported by dedicated autoimmune trials.
There is also a conceptual problem worth understanding. Autoimmune disease involves an immune system that is already overactive against the body's own tissue. A peptide that broadly stimulates immune activity is not obviously helpful in that setting, and could in theory make things worse. This is exactly why autoimmune treatment is built around carefully studied, often immune-calming therapies rather than general immune "boosters," and why importing immune-stimulating peptides into autoimmune care without specialist oversight is risky.
Are there FDA-approved peptides for UCTD or autoimmune disease?
No. There are no FDA-approved peptides for undifferentiated connective tissue disease (UCTD) or for autoimmune disease generally. UCTD and other autoimmune conditions are managed with established medications under specialist care. Anyone marketing a peptide as an approved autoimmune therapy is misrepresenting its status.
It helps to know why peptides are so heavily marketed despite this. They sit in a regulatory gray zone, they can be sold as research chemicals with little oversight, and "natural immune modulation" is an appealing message to patients frustrated by side effects of conventional drugs. That frustration is real and valid. But the answer is to work with your specialist on adjusting approved therapy, not to substitute an unproven, unregulated injectable. If conventional treatment is not controlling your disease or is causing intolerable side effects, that is a conversation to have with your rheumatologist, who may have approved options you have not tried.
Can you combine peptides with autoimmune medications?
This is a genuine safety concern, not a casual yes. Many autoimmune patients take immunosuppressants, biologics, or corticosteroids. Adding an unregulated, unapproved peptide that influences the immune system could, in theory, interfere with those treatments or trigger unpredictable immune effects, and there is no good human data to reassure you either way. The old page's claim that peptides "can be safely combined with biologics and corticosteroids" is not supported. Do not combine anything without your treating specialist's knowledge.
How FormBlends fits in
This article is educational only, and it is not a substitute for care from your rheumatologist or specialist. FormBlends follows the science on these compounds closely as the regulatory and clinical picture develops.
FormBlends offers physician-supervised, compounded GLP-1 weight management with semaglutide and tirzepatide. Obesity worsens systemic inflammation and can aggravate some autoimmune conditions, so for some patients, supervised weight management is a legitimate, evidence-based piece of an overall plan built with their specialist.
Frequently asked questions
Are any peptides FDA-approved for autoimmune disease? No. No peptide is FDA-approved to treat RA, lupus, MS, IBD, or UCTD.
What is the most advanced autoimmune peptide? Lupuzor (P140) for lupus, which has reached late-stage trials but is still investigational and not approved.
Does BPC-157 treat lupus or autoimmune disease? No. Its evidence is mostly animal-based, it is not FDA-approved, and it was placed in FDA Category 2 for compounding in 2023.
Can thymosin alpha-1 treat autoimmune conditions? Its human trials are for hepatitis B and cancer support, not autoimmune disease. It is not US-approved and using it for autoimmunity is off-label and unproven.
Can I take peptides with my biologic or steroid? Not without your specialist's guidance. There is no good safety data, and immune-active peptides could interfere with your treatment.
Should peptides replace my autoimmune medication? No. Approved therapies prescribed by your specialist are the evidence-based treatment. Do not stop them for an unapproved peptide.
Sources
- Zimmer / Lupuzor (P140, forigerimod) lupus clinical trial program, PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=P140+forigerimod+lupus
- Garaci E. et al., Thymosin alpha 1 clinical use (hepatitis B, oncology), PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=thymosin+alpha+1+hepatitis
- FDA, Bulk drug substances nominated for compounding under 503A (Category 2 includes BPC-157): https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdc-act
- FDA, Compounding and the FDA, questions and answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- American College of Rheumatology, treatment guidelines overview: https://rheumatology.org/clinical-practice-guidelines
Talk to a licensed provider
Start your free assessment. A licensed provider reviews every request before anything is prescribed, and not everyone qualifies.
Start the assessment →